IP Library Granted Patent US 7,399,877
Granted Patent B2
US 7,399,877 · App. 10/549,630 · Granted Jul 15, 2008

Phospholipid derivative

Assignees: NOF Corporation; Daiichi Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,399,877
App. No.
10/549,630
Granted
Jul 15, 2008
Kind
B2
Abstract

A phospholipid derivative represented by the following formula (I) wherein R 1 CO and R 2 CO independently represent an acyl group; R 3 represents hydrogen atom, or a hydrocarbon group; symbol “a” represents an integer of 0 to 4; symbol “b” represents 0 or 1, provided that when a is 0, b is 0; X represents hydrogen atom, an alkali metal atom, an ammonium, or an organic ammonium; A 1 O and A 3 O represent an oxyalkylene group containing oxyethylene group, wherein the ratio of the oxyethylene group to the oxyalkylene group in A 1 O and A 3 O is 0.5 or larger in terms of a weight ratio; A 2 O represents an oxyalkylene group; symbols “m” and “q” represent an average molar number of added oxyalkylene groups; and symbol “n” represent an average molar number of added oxyalkylene groups; provided that m, n and q satisfy the following conditions: 5≦m≦600, 1≦n≦45, 0≦q≦200, 10≦m+n+q≦600, 0.04≦n/(m+n+q), and q/(m+n+q)≦0.8, which can thicken the water shell of liposome surface by suppressing the spreading of the polyalkylene oxide structure on the surface and thus increase stability of the liposome

Claims (24)

1. A phospholipid derivative represented by the following formula (I):

wherein R 1 CO and R 2 CO independently represent an acyl group having 8 to 22 carbon atoms; R 3 represents hydrogen atom, or a hydrocarbon group having 1 to 4 carbon atoms; symbol “a” represents an integer of 0 to 4; symbol “b” represents 0 or 1, provided that when a is 0, b is 0; X represents hydrogen atom, an alkali metal atom, an ammonium, or an organic ammonium; A 1 O and A 3 O independently represent an oxyalkylene group containing oxyethylene group and having 2 to 4 carbon atoms, wherein the ratio of the oxyethylene group to the oxyalkylene group having 2 to 4 carbon atoms in A 1 O and A 3 O is 0.5 or larger in terms of a weight ratio; A 2 O represents an oxyalkylene group having 3 or 4 carbon atoms; symbols “m” and “q” independently represent an average molar number of added oxyalkylene groups having 2 to 4 carbon atoms; and symbol “n” represent an average molar number of added oxyalkylene groups having 3 or 4 carbon atoms; provided that m, n and q satisfy the following conditions:

5≦ m≦ 600, 1≦ n≦ 45, 0≦ q≦ 200, 10≦ m+n+q≦ 600, 0.04≦ n /( m+n+q ), and q /( m+n+q )≦0.8.

2. A phospholipid derivative represented by the following formula (II):

wherein R 1 CO and R 2 CO independently represent an acyl group having 8 to 22 carbon atoms; R 3 represents hydrogen atom, or a hydrocarbon group having 1 to 4 carbon atoms; symbol “a” represents an integer of 0 to 4; symbol “b” represents 0 or 1, provided that when a is 0, b is 0; X represents hydrogen atom, an alkali metal atom, an ammonium, or an organic ammonium; EO represents oxyethylene group; AO represents an oxyalkylene group having 3 or 4 carbon atoms; {(EO)s/(AO)t} represents a group consisting of randomly bonded oxyethylene groups and oxyalkylene groups having 3 or 4 carbon atoms, wherein the ratio of the oxyethylene groups to the oxyalkylene groups having 2 to 4 carbon atoms in {(EO)s/(AO)t} is 0.5 to 0.95 in terms of a weight ratio; symbol “s” represents an average molar number of added oxyethylene groups; and symbol “t” represent an average molar number of added oxyalkylene groups having 3 or 4 carbon atoms; provided that s and t satisfy the following conditions:

5≦ s≦ 500, 0≦ t≦ 100, and 6≦( s+t )≦500.

3. The phospholipid derivative according to claim 1 , wherein A 1 O and A 3 O are oxyethylene groups.

4. The phospholipid derivative according to claim 1 , wherein A 1 O and A 3 O are oxyethylene groups, and A 2 O is oxypropylene group.

5. The phospholipid derivative according to claim 1 , wherein A 1 O is oxyethylene group, A 2 O is oxypropylene group, and q is 0.

6. The phospholipid derivative according to claim 2 , wherein AO is oxypropylene group, and the ratio of oxyethylene groups to oxyethylene groups and oxypropylene groups is 0.60 to 0.95.

7. A lipid membrane structure comprising the phospholipid derivative according to claim 1 .

8. A pharmaceutical composition containing the lipid membrane structure according to claim 7 and a medicament.

9. The pharmaceutical composition according to claim 8 , wherein the medicament is an antitumor agent.

10. A surfactant comprising the phospholipid derivative according to claim 1 .

11. A lipid membrane structure comprising the phospholipid derivative according to claim 2 .

12. A lipid membrane structure comprising the phospholipid derivative according to claim 3 .

13. A lipid membrane structure comprising the phospholipid derivative according to claim 4 .

14. A lipid membrane structure comprising the phospholipid derivative according to claim 5 .

15. A lipid membrane structure comprising the phospholipid derivative according to claim 6 .

16. A surfactant comprising the phospholipid derivative according to claim 2 .

17. A surfactant comprising the phospholipid derivative according to claim 3 .

18. A surfactant comprising the phospholipid derivative according to claim 4 .

19. A surfactant comprising the phospholipid derivative according to claim 5 .

20. A surfactant comprising the phospholipid derivative according to claim 6 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2013
From: DAIICHI SANKYO COMPANY, LIMITED
To: NOF CORPORATION
Reel/Frame 030187/0922 →
MERGER Recorded Jan 29, 2013
From: DAIICHI PHARMACEUTICAL CO., LTD.
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 029717/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2006
From: ITOH, CHIKA; OHHASHI, SYUNSUKE; KUBO, KAZUHIRO; YASUKOHCHI, TOHRU; KIKUCHI, HIROSHI; SUZUKI, NORIO; TAKAHASHI, MIHO; YAMAUCHI, HITOSHI
To: NOF CORPORATION; DAIICHI PHARMACEUTICAL CO., LTD.
Reel/Frame 018205/0258 →
Priority Claims (1)
JP 2003-077242 · Mar 20, 2003 · national
Continuity (1)
Related Publication 20070031481A1 · Feb 8, 2007